Research programme: hydroxysteroid dehydrogenase inhibitors - Merck
Latest Information Update: 29 Aug 2011
At a glance
- Originator Merck & Co
- Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for Metabolic syndrome in USA (unspecified route)
- 06 Apr 2006 Preclinical trials in Metabolic syndrome in USA (unspecified route)